EXCLUSIVE-US FDA launches fresh safety scrutiny of approved RSV therapies for infants
The US FDA is conducting a fresh safety review of approved RSV therapies for infants from Merck, Sanofi, and AstraZeneca, following concerns from vaccine skeptics. The scrutiny, initiated by FDA officials, questions the safety of these therapies, despite studies showing no seizure risk. The FDA's inquiry underscores the seriousness of the situation, although no immediate actions have been taken. The therapies, which provide ready-made antibodies to infants, are part of the CDC's recommended immunization schedule and have shown to reduce RSV hospitalizations.
